Physician profile
Catherine J Evans
NPI 1710039276
$292.04
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $248 · 2020: $44.45.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $57.85 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $27.08 | 2019 | |
| Janssen Pharmaceuticals, INC | $24.88 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $21.30 | 2019 | |
| Abbvie INC. | $20.24 | 2020 | |
| Cumberland Pharmaceuticals, INC. | $20.17 | 2019 | |
| Novo Nordisk INC | $20.11 | 2019 | |
| Boston Scientific Corporation | $16.91 | 2019 | |
| Shire North American Group INC | $16.74 | 2019 | |
| Daiichi Sankyo INC. | $15.72 | 2019 | |
| Avanir Pharmaceuticals, INC. | $13.01 | 2019 | |
| Merck Sharp & Dohme LLC | $12.89 | 2019 | |
| Pfizer INC. | $12.69 | 2019 | |
| Karyopharm Therapeutics INC. | $12.45 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Catherine Evans listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.